Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected With a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1)

NCT03412643 is registered in ClinicalTrials.gov with NSABP Foundation Inc as lead sponsor.

NCT NCT03412643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03412643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected With a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1)
Lead sponsor
NSABP Foundation Inc
Phase
Phase 2
Overall status
Unknown status
Start date
May 14, 2018
Completion date
October 30, 2023
Enrollment
64 (estimated)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

her2-negative breast cancer